Advertisement
DHR vs MTD
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Mettler-Toledo International Inc. (MTD) Stock Comparison
Key Takeaways
- DHR boasts a larger market capitalization of approximately $123 billion compared to MTD's $25 billion, offering greater scale and diversification across biotechnology, life sciences, and diagnostics.
- DHR has delivered stronger year-to-date (YTD) performance at +24.10%, outperforming MTD's +9.77%, though both have faced recent market pressures.
- Recent weeks have seen DHR decline toward its 52-week low amid a $908 million acquisition-related charge, while MTD maintains relative stability ahead of Q1 earnings.
- Both stocks exhibit solid profitability, with DHR's P/E ratio (price-to-earnings) at 33.53 and MTD's at 29.90, reflecting premium valuations in the precision instruments sector.
- DHR's advancing Masimo acquisition positions it for growth in patient monitoring, contrasting MTD's focus on organic precision lab tools expansion.
Introduction
Danaher Corporation (DHR) and Mettler-Toledo International Inc. (MTD) are leading players in the precision instruments and life sciences equipment sector, serving pharmaceuticals, biotech, and research labs. This stock comparison analyzes their business models, recent performance, and market positioning amid evolving healthcare demands. Traders seeking exposure to diagnostics and lab analytics, or investors eyeing sector growth drivers like M&A (mergers and acquisitions) and innovation, will find value in understanding their relative strengths, momentum, and risks in the current market environment.
DHR Overview and Recent Performance
Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products across biotechnology, life sciences, and diagnostics segments. With a market cap of $122.7 billion and shares trading around $173, the stock nears its 52-week low of $172 amid recent market activity. In recent weeks, DHR has declined about 1.3%, influenced by a $908 million charge tied to its advancing acquisition of Masimo at $180 per share, expected to close in 2026. Q1 results showed revenue of $5.95 billion and core sales growth of 0.5%, supporting EPS of $1.45, while YTD gains stand at +24.10%. Sentiment reflects optimism on earnings quality and deal synergies despite short-term pressures.
MTD Overview and Recent Performance
Mettler-Toledo International Inc. (MTD) manufactures precision instruments including laboratory balances, pipetting solutions, and industrial weighing systems, operating across U.S., Swiss, European, Chinese, and other regions. Shares trade near $1,258 with a $25.5 billion market cap, positioned between its 52-week high of $1,525 and low of $1,052. Recent market activity shows modest 1-month stability around flat, with YTD performance at +9.77%, trailing broader gains amid stagnant revenue concerns. Investors await Q1 earnings on May 7, forecasting EPS growth, buoyed by strong profitability (P/E 29.90, EPS $42.07 TTM) and analyst buy ratings. Sentiment balances resilience in lab demand against slower growth.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available models that trade thousands of tickers across diverse strategies and timeframes. These bots deliver real-time signals for copy trading, featuring annualized returns from +23% to +162% and win rates of 51% to 88%, with short-term focuses like 5-minute to 60-minute charts using AI/ML trend trading, take-profit/stop-loss corridors (e.g., TP 3%/SL 2%), and multi-agent systems. Covering sectors such as semiconductors, industrials, and ETFs with 3-18 tickers per bot, they adapt to current conditions for optimal performance. Explore these tools to enhance your trading with data-driven insights tailored to volatile markets.
Head-to-Head Comparison
DHR’s conglomerate model emphasizes M&A-driven growth, contrasting MTD’s specialized focus on precision analytics and weighing solutions. Growth drivers for DHR include the Masimo deal expanding diagnostics, while MTD relies on lab demand and software like LabX. Recent momentum favors neither decisively, with DHR’s YTD edge offset by volatility and MTD’s steadier range. Risk factors involve acquisition integration for DHR and revenue stagnation for MTD, both exposed to healthcare R&D (research and development) cycles. Market sentiment tilts toward DHR’s scale but notes MTD’s higher EPS efficiency.
Tickeron AI Verdict
Tickeron’s AI currently leans toward DHR with higher probability for near-term upside, driven by acquisition catalysts, superior YTD relative performance, and diversified stability amid sector headwinds. MTD offers appeal for focused precision plays but trails in momentum and scale. Observable trends suggest monitoring both for earnings catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Hold and MTD is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileMTD’s FA Score has 1 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 4 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 3 bearish.
- MTD’s TA Score: 4 bullish, 6 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -5.40% price change this week, while MTD (@Medical Specialties) price change was -8.25% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +10.58%. For the same industry, the average monthly price growth was +4.66%, and the average quarterly price growth was -5.70%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
MTD is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical Specialties (+10.58% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | MTD | DHR / MTD | |
| Capitalization | 115B | 20.8B | 553% |
| EBITDA | 7.08B | 1.24B | 569% |
| Gain YTD | -29.121 | -26.004 | 112% |
| P/E Ratio | 31.38 | 24.23 | 129% |
| Revenue | 24.8B | 4.03B | 616% |
| Total Cash | 5.7B | 66.9M | 8,522% |
| Total Debt | 18.5B | 2.15B | 860% |
DHR | MTD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 78 | 3 | |
PRICE GROWTH RATING 1..100 | 65 | 65 | |
P/E GROWTH RATING 1..100 | 65 | 65 | |
SEASONALITY SCORE 1..100 | 44 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (20) in the Medical Specialties industry is significantly better than the same rating for MTD (99). This means that DHR’s stock grew significantly faster than MTD’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MTD (100). This means that DHR’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is significantly better than the same rating for DHR (78). This means that MTD’s stock grew significantly faster than DHR’s over the last 12 months.
MTD's Price Growth Rating (65) in the Medical Specialties industry is in the same range as DHR (65). This means that MTD’s stock grew similarly to DHR’s over the last 12 months.
MTD's P/E Growth Rating (65) in the Medical Specialties industry is in the same range as DHR (65). This means that MTD’s stock grew similarly to DHR’s over the last 12 months.
| DHR | MTD | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 69% | 3 days ago 75% |
| Stochastic ODDS (%) | 3 days ago 64% | 3 days ago 69% |
| Momentum ODDS (%) | 3 days ago 69% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 68% | 3 days ago 67% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 66% | 3 days ago 66% |
| Advances ODDS (%) | 11 days ago 54% | 12 days ago 63% |
| Declines ODDS (%) | 3 days ago 60% | 5 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 65% | 3 days ago 74% |
| Aroon ODDS (%) | N/A | 3 days ago 68% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DVXF | 23.29 | N/A | N/A |
| WEBs Financial XLF Defined Vol ETF | |||
| EVSM | 50.16 | -0.07 | -0.14% |
| Eaton Vance Short Dur Muncpl Inc ETF | |||
| ABCS | 31.46 | -0.31 | -0.98% |
| Alpha Blue Capital US Sm-Md Cp Dyn ETF | |||
| JHS | 11.01 | -0.15 | -1.32% |
| John Hancock Income Securities Trust Capital Stock | |||
| EWY | 178.86 | -11.66 | -6.12% |
| iShares MSCI South Korea ETF | |||
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.